All Outputs (7)

MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer (2017)
Presentation / Conference
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., …Cortes Castan, J. (2017, December). MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Paper presented at 2017 San Antonio Breast Cancer Symposium, San Antonio, Texas

Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being one of the main drivers. Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endoc... Read More about MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. (2017)
Journal Article
Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., …Bliss, J. M. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet, 390(10099), 1048 - 1060. https://doi.org/10.1016/S0140-6736%2817%2931145-5

BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy r... Read More about Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial..

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial (2017)
Journal Article
Cameron, D., Morden, J. P., Canney, P., Velikova, G., Coleman, R., Bartlett, J., …Bliss, J. M. (2017). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, 18(7), 929 - 945. https://doi.org/10.1016/S1470-2045%2817%2930404-7

Background Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence... Read More about Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.

Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial (2017)
Presentation / Conference
Coles, C., Griffin, C., Kirby, A., Agrawal, R., Alhasso, A., Bhattacharya, I., …Bliss, J. (2017, May). Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Paper presented at ESTRO 36, Vienna, Austria

Conference abstract. Part of special issue: ESTRO 36, May 5-9, 2017, Vienna, Austria.

Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy (2017)
Journal Article
Brunt. (2017). Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy. Radiotherapy and Oncology, 123(S1), S136 - S137. https://doi.org/10.1016/S0167-8140%2817%2930708-9

Conference abstract. part of Special Issue ESTRO 36, May 5-9, 2017, Vienna, Austria.

Bone Mineral Density Screening in Invasive Breast Cancer Patients Treated with Anastrozole in Adjuvant Setting (2017)
Journal Article
Pai, K., Gilani, S., & Brunt, A. (2017). Bone Mineral Density Screening in Invasive Breast Cancer Patients Treated with Anastrozole in Adjuvant Setting. Clinical Oncology, 29(6), e102 - e103. https://doi.org/10.1016/j.clon.2017.01.031

Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose? (2017)
Report
Price, L., & Brunt, A. M. (2017). Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?

Trastuzumab (Herceptin) is used in neoadjuvant, adjuvant and metastatic breast cancer. Infusion reactions are a common side effect most of which are mild and easily managed, anaphylaxis occurs rarely. The summary of product characteristics recommends... Read More about Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?.